18 Feb 2021

Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA

Investors | Therapeutics

01 Feb 2021

AffyXell $7.3 Million Series A Financing

Investors | Therapeutics

07 Jan 2021

License Agreement with POINT Biopharma Inc

Investors | Therapeutics

23 Dec 2020

Submission of Clinical Trial Application for AVA6000 Pro-doxorubixin

Investors | Therapeutics

27 Oct 2020

ShareBuyers Interview with Alastair Smith

Diagnostics | Investors | Therapeutics

18 Aug 2020

Avacta and LG Chem Life Sciences Expand Partnership

Investors | Therapeutics

11 Aug 2020

Avacta Appoints Therapeutics Chief Development Officer

Investors | Therapeutics

30 Jul 2020

Innovations in neutralising therapies

Blogs | Therapeutics

29 Jul 2020

Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutralising Affimer Therapy

Investors | Therapeutics

18 Jun 2020

Update on Affimer^® Therapy for COVID-19 Infection

Investors | Therapeutics